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A B S T R A C T
Information on equine infectious anaemia (EIA) in mules, including those with an equivocal reaction in
agar gel immunodiffusion test (AGIDT), is scarce. For this, a study was conducted to evaluate the clinical,
viral loads and pathological ﬁndings of two groups of naturally infected asymptomatic mules,
respectively with a negative/equivocal and positive AGIDT reactivity, which were subjected to
pharmacological immune suppression (IS). A non-infected control was included in the study that
remained negative during the observation period. Throughout the whole study, even repeated episodes
of recrudescence of EIA were observed in 9 infected mules, independently from their AGIDT reactivity.
These events were generally characterised by mild, transient alterations, typical of the EIA acute form
represented by hyperthermia and thrombocytopenia, in concomitance with viral RNA (vRNA) peaks that
were higher in the Post-IS period, reaching values similar to those of horses during the clinical acute
phase of EIA. Total tissue viral nucleic acid loads were greatest in animals with the major vRNA activity
and in particular in those with negative/equivocal AGIDT reactivity. vRNA replication levels were around
10–1000 times lower than those reported in horses, with the animals still presenting typical alterations
of EIA reactivation. Macroscopic lesions were absent in all the infected animals while histological
alterations were characterised by lymphomonocyte inﬁltrates and moderate hemosiderosis in the
cytoplasm of macrophages. On the basis of the above results, even mules with an equivocal/negative
AGIDT reaction may act as EIAV reservoirs. Moreover, such animals could escape detection due to the low
AGIDT sensitivity and therefore contribute to the maintenance and spread of the infection.
ã 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Equine infectious anaemia (EIA) is a viral disease that affects all
domestic members of the genus Equus spp. (horse, donkey and
mule) and is characterised by intermittent fever, progressive
anaemia, emaciation and death in severe cases. Clinical forms of
EIA are acute, chronic and inapparent, with the latter being the* Corresponding author.
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0378-1135/ã 2016 The Authors. Published by Elsevier B.V. This is an open access article unmost frequent. Animals in the chronic and inapparent phase may
experience a recrudescence of the infection as a consequence of
severe stress, hard work or the presence of other diseases
(Quinlivan et al., 2007). EIA virus (EIAV), a Lentivirus of the
Retroviridae family, is responsible for the infection that is
characterised by a restricted tropism for the equine monocyte-
macrophage lineage with productive replication occurring only in
the differentiated tissue macrophages (Oaks et al., 1998).
During the surveillance programme conducted in Italy, between
2007 and 2012, that used the ELISA as a screening test and agar gel
immunodiffusion test (AGIDT) as a conﬁrmatory test, prevalence in
mules was found to be signiﬁcantly higher than in horses and
donkeys (Sala et al., 2012). In addition, equivocal AGIDT reactions
were more frequent among this hybrid species (Scicluna et al.,
2013).der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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AGIDT reactions are respectively described for horses, by
McConnell and Katada, (1981) and by Issel and Adams (1982),
in which the authors succeeded in the transmission of EIAV from
such animals. Similar investigations were also conducted to
evaluate the correlation of the AGIDT serological reactivity
pattern with plasma viral loads at different time intervals and
in the tissues of experimentally infected horses (Harrold et al.,
2000; Hammond et al., 2000). In addition, in a study conducted by
Cook et al. (2003), the authors report that the acute form of the
disease in the horse is characterised by the typical EIA alterations
of hyperthermia and thrombocytopenia which are observed when
the plasma viral RNA (vRNA) copies exceed concentrations of
log10 7.7/ml, deﬁned as the pathogenic threshold (Cook et al.,
2001). Different was the evolution observed in donkeys as these
animals maintained low viremic levels in the absence of clinical
signs (Cook et al., 2001).
Clinical and virolgical studies on EIA in mules are limited to
two publications, in which the authors, in one of them (Spyrou
et al., 2003), describe in detail the evolution of the natural and
experimental infection observed in two subjects for each
condition, for a time period that was however insufﬁcient to
completely elucidate this. Also, the presence of EIAV in these
animals was reported only qualitatively. Considering the
relatively high EIA prevalence levels in the Italian mule
population and their elevated density in restricted areas where
they are used as working animals, the scientiﬁc literature on the
importance of the role that they might play as EIAV reservoirs is
to date scarce. In view of this, an observational study was
conducted to assess the clinical, pathological and virological
parameters of naturally EIA infected mules having equivocal/
negative AGIDT reactions, according to the scoring system
proposed by Issel et al. (1999). In addition, the results obtained
from these animals were compared to those having a clearly
positive AGIDT reaction. As all the study animals were
presenting an inapparent form of the infection, they were
subjected to a pharmacological immune suppression (IS) as
described by Craigo et al. (2007) for the reactivation of the
disease. Further to the serological ﬁndings, already described by
Scicluna et al. (2013), this paper reports the clinical evolution of
EIA, in relation to the plasma vRNA levels, with the aim to
investigate the correlations among these characteristics and
evaluate the results in relation to the risk such animals may
represent in the epidemiology of EIA. Viral replication was
assessed in terms of vRNA copies in plasma, as well as, total viral
nucleic acid loads (viral DNA and RNA) and presence of gross and
histological lesions in tissues of various organs collected at the
end of the study period (SP).Table 1
Details of the characteristics of the study group: identiﬁcation, age, gender, serological
Mule identiﬁcation no. Age Gender Serological results (ELISA/AGIDT
On recruitment At the e
1 12 F +/2/+ +/2/+ 
2 2 F +/3/+ +/3/+ 
3 30 F +/0/+ +/0/+ 
4 22 F +/3/+ +/3/+ 
5 9 F +/1/+ +/2/+ 
6 8 F /0/+ /0/+ 
7 11 C +/1/+ +/1/+ 
8 17 F +/1/+ +/1/+ 
9 11 F +/2/+ +/4/+ 
10 7 F +/3/+ +/4/+ 
a Serological results for ELISA and IB are reported qualitatively as positive (+) or negati
b AGIDT reactivity group: N mules with negative (score 0) or equivocal (score 1) rea2. Materials and methods
2.1. Experimental animals and design
Ten mules, arbitrarily identiﬁed as they were enrolled from 1 to
10, were acquired from ﬁve distinct EIA outbreaks that had occurred
in ﬁve neighbouring provinces of Central Italy. The age, sex and
serological status for EIAV, of the experimental animals recorded on
recruitment, are reported in Table 1. The ten animals were divided
into two groups on the basis of their AGIDT reactivity observed at the
start of the experiment: ﬁve mules had either equivocal or negative
reactions (Group N) while the remaining animals presented a clear
precipitation identity band (Group P), (Scicluna et al., 2013). A
negative control, Mule 11, was included in the study that was
howeverkept isolatedfromthe infectedanimals,butsubjectedtothe
same experimental conditions adopted for the other ten mules.
Clinical examination and sampling of the negative control were
carried out with the same frequency and using the same methods as
those described for the infected animals. To ensure its persistent
negative status, the EIAV tests on this animal were extended to
30 days after the end of the SP.
The study design was approved by the competent authorities
(Italian Ministry of Health – identiﬁcation No IZS 02/10 RC). Animal
husbandry and experimental procedures adopted throughout the
SP, that lasted for a minimum of 84 days, were conducted under
veterinary supervision and in compliance with the European Union
Regulations in force for the use of animals in experiments.
Biosecurity measures, as prescribed by the National Regulations,
were also adopted to ensure that no EIAV transmission occurred
from these animals.
2.2. Pharmacologically induced immune suppression
The mules included in the study underwent IS to induce EIAV
reactivation. The treatment protocol, described by Kono et al.
(1976) and Tumas et al. (1994), started on day 56 from the start of
the SP using dexamethasone (Rapison1) at 0.11 mg/kg body
weight/die. The duration of the pharmacological administration
for each animal was based on the Delayed Type Hypersensitivity
(DTH) reaction obtained by the inoculation of Phaseolus vulgaris
agglutinin1 (PHA – Sigma) with the same procedure described by
Baus et al. (1996).
2.3. Clinical examination
The general condition of the animals, including the clinical
signs considered as characteristic of an acute form of EIA, results observed on recruitment and at the end of OP.
/IBa) AGIDT reactivity groupsb Duration of IS treatment in days
nd of SP
P 10
P 8
N 8
P 8
N 8
N 8
N 8
N 8
P 8
P 8
ve (). The AGIDT reactivity is reported as a score as described by Issel et al. (1999).
ctivity and P mules with clear reactivity (score 2–5).
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(Leroux et al., 2004), were blindly recorded during a complete
physical examination, conducted daily for the whole SP, at the
same hour by one clinician to reduce variability in their
registration. Threshold for hyperthermia was set at a rectal
temperature above 39 C as reported for horses in similar studies,
(Issel et al., 2014).
2.4. Sample collection for laboratory examinations
During the daily clinical examination of the animals, blood,
with and without EDTA, were collected from each animal for the
laboratory tests described in the present paper. For the estimation
of vRNA, plasma was obtained from EDTA blood as follows;
volumes of 5 ml of blood were processed on collection by
centrifugation at 500g for 5 minutes (min) to separate the
plasma from the erythrocytes. The plasma was transferred into a
new tube, centrifuged at 1200g for 30 min and the resulting
plasma was collected and stored. Nasal swabbing was performed to
verify active infections due to equine herpesvirus 1 and 4 and to
investigate the possible elimination of EIAV through this route in
relation to the presence of the virus in the lungs of affected horses
as described by Quinlivan et al. (2007) and Bolfa et al. (2013). On
collection, the swabs were immediately immersed in 0.5 ml of
phosphate buffer solution (PBS). The supernatant of these samples
was collected after centrifugation for 20 min at 1000g. Blood
serum was obtained by centrifugation for 10 min at 179g. At the
end of the SP, the animals were slaughtered according to the
Regulations in force and subjected to necropsy. Tissue samples of
the following organs were collected: brain, spinal cord, spleen,
lung, heart, mediastinal and mesenteric lymph nodes, liver, kidney
and adrenal gland. Samples for virological and serological tests
were stored at 80 C and 20 C respectively until further
examination, and in the case of histological and immunohisto-
chemical analyses, organ samples were processed as described
further on.
2.5. Serological and biomolecular methods for pathogens other than
EIA
On recruiting, the animals were veriﬁed for the presence of
infections that could cause a similar clinical picture or inﬂuence
the evolution of the EIA infection during the study period. The
infections considered were based on the local epidemiological
situation and clinical pictures similar to EIA that these could
induce, as in the case of equine piroplasmosis (EP) caused by T. equi
and B. caballi or immune suppression due to equine herpes virus
(EHV) 1 and 4. Testing for presence of these etiological agents was
carried out as follows: the serum of the experimental animals was
tested for antibodies against equine piroplasms using Babesia equi/
caballi Antibody test Kits, cELISA–VMRD, Inc.1. EDTA blood
samples were used for the molecular detection of the two
protozoa, employing commercial PCR kits, Babesia equi/caballi
Genesig1 Advanced (PrimerdesignTM Ltd, Southampton, United
Kingdom). Animals positive for EP were treated with Imidocarb1
(Intervet), a week before the start of the SP, with the dosage
indicated for the sterilization of the two protozoa. For EHV 1 and 4,
vaccination using Pneumabort K1 (Fort Dodge Laboratories) was
administered three weeks prior to the start of the SP, followed by a
booster four weeks later.
The efﬁcacy of the EP treatment was veriﬁed by retesting the
subjects using PCR, two weeks after treatment and again weekly
throughout the whole SP. Presence of EHV 1 and 4 infections were
also monitored on weekly basis, using a Real Time PCR (RT PCR) as
described by Damiani et al. (2005).2.6. Bacteriological examinations
For this purpose, nasal swabs were collected and immediately
immersed in Stuart’s transport medium and stored at 20 C for
further use. Bacteriological examinations were carried out only if
an animal presented clinical signs referable to a respiratory
infection of bacterial origin.
2.7. Haematological and PCR methods for EIA
2.7.1. Platelet count (PLT)
The PLT count was performed on EDTA blood, within an hour of
its collection, using an automated Cell-Dyn 37001 (Abbott). As no
reference baseline for this parameter is available in mules, the
value adopted was that reported for horses at 1 105 platelets/ml
(Issel et al., 2014). All the study animals had pre-SP values above
the established baseline during the one-week observation period
preceding the start of the experiment (data not shown).
2.7.2. Plasma vRNA loads
The evolution of EIAV replication in the mules was assessed as
reported by Cook et al. (2003) and Quinlivan et al. (2007) through
the quantitation of the vRNA in the plasma, collected on daily basis.
vRNA levels were deﬁned using a qRT PCR as described by Scicluna
et al., 2013; targeting a region of the exon 1 of the tat gene of EIAV.
Total RNA was extracted in double replicate from a volume of
140 ml of each plasma sample using the QIAamp Viral RNA Mini kit
(Qiagen, Hilden, Germany) and employing the automatic extractor
QIAcube (Qiagen, Hilden, Germany). Reverse transcription was
conducted employing High Capacity cDNA Reverse Transcription
Kit (Applied Biosystems, Foster City, CA, USA) on 200 ng of the
extracted RNA, concentration established using the NanoDrop
1000 Spectrophotometer (Thermo Fisher Scientiﬁc Inc., Wilming-
ton, DE, U.S.A.). The total reaction volume was 60 ml, of which 30 ml
contained 200 ng of the extracted RNA, with the addition of the
following reagents: 6 ml of 10 random hexamer primers, 6 ml 10X
RT-Buffer, 2.4 ml dNTP mix 100 mM, 3 ml of 5 U Multi Scribe
Reverse Transcriptase and 12.6 ml of H2O-DEPC. Synthesis of the
cDNA was carried out using AB Veriti 96 well Thermal Cycler
(Applied Biosystems, Carlsbad, USA) with the following thermal
proﬁle: 25 C for 10 min, 37 C for 120 min, 85 C for 5 min.
The exon 1 of the tat gene of EIAV was used as target of the
following primers and probe: MkIII Forward: 50-GGC GCC CGA ACA
GGG ACC-30. MkIII Reverse: 50-TGG CCA GGA ACA CCT CCA GAA
GAC-30. The probe employed is a Fluorescent Locked Nucleic Acid
(LNA): 50-FAM-T[+G]A ACC T[+G]G [+C]TG ATC G[+T]A G[+G]A-30
BHQ. The qRT-PCR, was carried out using the TaqMan Universal
PCR Master Mix kit (Applied Biosystems, Foster City, CA, USA) with
the following composition: 12.5 ml of TaqMan 2X Universal PCR
Master Mix (Applied Biosystems, Foster City, CA, USA), 900 nM of
each primer, 300 nM of probe, 5 ml of cDNA and H2O-DEPC to reach
a total volume of 25 ml. The thermal proﬁles of the qRT-PCR, using
AB 7900HT Fast Real-Time PCR System, were as following: 95 C for
10 min, and 50 cycles of 95 C for 15 s, 52 C for 30 s and 60 C for
1 min. A quantiﬁed control, developed as described further on, was
included in each qRT-PCR run for the estimation of the vRNA
copies/ml of the plasma sample. All data were analysed using the
ABI 7900HT Sequence Detection Systems software package ver. 2.4
(Applied Biosystems, Foster City, CA, USA).
The limit of detection (LOD) of the assay was established using
the in vitro transcribed RNA, obtained from the plasma of Mule
4 using the EIAV MkIII primers. Different Log10 concentrations of
the transcribed RNA were prepared to cover a range between
3.77  109 to 0.2 copies/ml. The limit of quantitation (LOQ) of the
qRT-PCR was deﬁned as 3.4 copies/ml while the LOD was 1 copy/
ml. The plasma vRNA load for each sample was determined by
Fig. 1. Temporal evolution of body temperature, platelet counts and plasma vRNA load of study animals.
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vRNA copies/ml. The Ct value of each plasma sample reported in
Fig. 1 represents the mean value obtained from the analyses of the
sample extracted and examined as a double replicate.
2.7.3. Total viral nucleic acid in tissues
For the quantitation of the total viral nucleic acid levels, that is
vRNA and vDNA in the tissues collected at slaughter,100 mg of each
tissue type were added to 1 ml of PBS and disrupted using
FastPrep1 FP120Cell Disrupter Instrument (Qbiogene, Inc. Europe)
in Lysing Matrix D tubes (MP Biomedicals, Santa Ana, California,
USA). Two hundred ml of the homogenized tissue were employed
for nucleic acid extraction with the automatic extractor QIAcube
(Qiagen, Hilden, Germany) using the QIAamp cador Pathogen Mini
Kit according to the manufacturer instructions. Each sample was
extracted in double and the average nucleic acid concentration was
measured using a NanoDrop 1000 Spectrophotometer (Thermo
Fisher Scientiﬁc Inc., Wilmington, DE, U.S.A.). The average number
of cells contained in each sample was estimated from the ratio of
the mean value of the nucleic acid concentration of the sample andTable 2
Histological, preliminary immunohistochemical (IHC) results and total nucleic acid vira
(positive), upper half of the table, and Group N (equivocal or negative), lower half.
GROUP P Mule No 1 (49) Mule No 2 (70) Mule No
HISTOLOGY IHC Viral
Load
(copies/
105 CE)
HISTOLOGY IHC Viral
Load
(copies/
105 CE)
HISTOLO
HS LI HS LI HS LI
Adrenal
Glands
na na na  na na na   
Brain  + /    / < LOQ na na
Heart  + /    /   + 
Kidney  + + 6.95  ++ / 0.20  ++
Liver +  + 5.93   /   ++
Lung na na na /  + / 0.47 na na
Mediastinal
Lymph
Nodes
  /    /   
Mesenteric
Lymph
Nodes
na na na /   / / na na
Spinal Cord   / 1.79   / 8.83 na na
Spleen ++  / 25.19   / 21.92 ++ 
GROUP N Mule No 3 (28) Mule No 5 (35) Mule No
HISTOLOGY IHC Viral
Load
(copies/
105 CE)
HISTOLOGY IHC Viral
Load
(copies/
105 CE)
HISTOLO
HS LI HS LI HS LI
Adrenal
Glands
na na na na   / 4.69  + 
Brain  ++ ? 50.99 na na na 0.15  + 
Heart  + /   + / 0.08  + 
Kidney na na na /  ++ / 0.63  + 
Liver + ++ + 50.1   / 29.76 + 
Lung  + +    + /  
Mediastinal
Lymph
Nodes
+  / 6.23   / 2.51  
Mesenteric
Lymph
Nodes
na na na /   / 9.86  
Spinal Cord na na na 254.94 na na na   
Spleen +  / 129.25 ++  / 487 ++ 
Histopathological results are reported with the following score system: '-' no lesions, ' + ' m
lesions); HS = hemosiderosis, LI = lymphomonocytic inﬁltrate. Total nucleic acid viral loa
positive, '-' negative, '?' presence of aspeciﬁc background, ‘na' not available, '/' not examinthe average cellular content of nucleic acids, using the reference
value reported on www.genomesize.com. This was carried out as
previously described for the horse by Harrold et al. (2000) and in
our case the assumptions used were that cells are diploid and in the
Gl phase of the cell cycle (Simmonds et al., 1990). In addition, we
assumed that the average cellular content of nucleic acids for the
leucocytes of mules, the only data available, is equal to that
contained in other tissues. The method used for the quantitation of
the total viral nucleic acid loads in tissues was as described for
vRNA.
The standardization of the nucleic acid viral loads in tissues was
obtained by reporting the quantitative PCR results as the number
of viral copies/100,000 cellular equivalent (105 CE).
2.7.4. Veriﬁcation of the presence of PCR inhibiting activity
Presence of inhibiting activity in the samples examined by the
PCR methods used was veriﬁed by the ampliﬁcation of the
endogenous gene coding for Beta-actin, using primers and probe
included in the PCR kit of Babesia equi/caballi Genesig1 Advanced
(PrimerdesignTM Ltd, Southampton, United Kingdom).l loads in the tissues examined, divided, according to AGIDT reactivity, in Group P
 4 (49) Mule No 9 (35) Mule No 10 (35)
GY IHC Viral
Load
(copies/
105 CE)
HISTOLOGY IHC Viral
Load
(copies/
105 CE)
HISTOLOGY IHC Viral
Load
(copies/
105 CE)
 HS LI HS LI
 / 1.16   /    + 1.73
 na    /    / 
/ 0.83   /   + + 
 +   ++ /   + + 60.83
 + 14.35 na na na    / 3.34
 na / na na na na na na na /
 / 1.37   /    / 
 na / na na na    / 15.54
 na 11.69 na na na    / 
 / 0.17 ++  / 46.86 ++   4.44
 6 (70) Mule No 7 (70) Mule No 8 (56)
GY IHC Viral
Load
(copies/
105 CE)
HISTOLOGY IHC Viral
Load
(copies/
105 CE)
HISTOLOGY IHC Viral
Load
(copies/
105 CE)
 HS LI HS LI
+  na na na  na na na 
/    /    / 
/   + /    / 
/   + /   + / 
 +    / 0.12   / 0.22
 + /  + + 0.37   / 
     / 1.3 ++  / 
  /   / / na na na 0.07
 /    /    / 
   +  / 40.34 ++  / 
ild (few and scattered lesions), ' + +' moderate to diffuse (multifocal to disseminated
d are reported as no copies/105 CE, <LOQ = inferior to the limit of quantiﬁcation. ' + '
ed. Number in brackets (n) refers to the day of slaughter after immune suppression.
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Portions of the organs collected during necropsy were
immediately ﬁxed in 10% neutral buffered formalin and submitted
to histological examination with the list of examined tissues
reported in Table 2. Four-micron tissue sections were stained with
hematoxylin-eosin (HE) and the microscopic ﬁndings were
recorded for the typical EIA-associated lesions (OIE, 2013),
hemosiderosis (HS) and lymphomonocytic inﬁltrates (LI) using
the following score system, based on the degree of severity: ‘’ no
lesions; ‘+’ mild (few and scattered lesions); ‘++’ moderate to
diffuse (multifocal to disseminated lesions). As for the recording of
clinical signs, the same pathologist registered all the histological
alterations and had no access to the results of the other tests
conducted on the same specimens.
In a preliminary trial, immunohistochemistry (IHC) was
conducted principally on samples with evident histological lesions,
using the following procedure: blocking of endogenous peroxidase
with 3% H2O2 at room temperature for 30 min, antigen retrieving in
citrate buffer solution (pH 6) in a water bath at 600 W in a
microwave oven for 11 min, followed by an incubation with goat
serum (Sigma-Aldrich, Inc., Missouri, US) at room temperature for
1 hour (h), washing in PBS followed by incubation with a primary
monoclonal antibody (MAb) anti-p26 (Scicluna et al., 2013) for 1 h
at room temperature. A positive reaction was detected using 3,30-
diaminobenzidine (EnVisionTM FLEX, Dako, Santa Clara, CA, US) as
chromogen with a 3-min development at room temperature and
counterstained with haematoxylin. Samples examined and relative
results are reported in Table 2 as presence (+) or absence () of a
positive reaction.
3. Results
As the aim of the study was to evaluate the evolution of clinical,
pathological parameters and viral loads of naturally EIA infected
mules having equivocal/negative AGIDT reactions, the results of
these animals (Group N – Mules 3, 5, 6, 7 and 8) were compared to
those presenting a clearly positive AGIDT reactivity (Group P –
Mules 1, 2, 4, 9 and 10).
3.1. Immune suppression
Dexamethasone administration was interrupted when the ratio
between the DTH skinfold thickness, induced by PHA inoculation
with that of the control reaction, was <1 (Kono et al., 1976 and
Tumas et al., 1994) indicative of an immune suppressed state. The
IS treatment was effective by day 8 in the eleven animals, with the
exception of Mule 1, in which IS was obtained on day 10. Side
effects due to steroid administration characterised by increased
heart rate and laminitis were never observed.
3.2. Clinical, haematological and molecular results
The animals were clinically controlled and sampled on daily
basis for 84 days, 56 days before and 28 days after the IS.
Samples that were examined to verify the presence of latent
infections for EP and EHV 1 and 4 were conﬁrmed as negative,
except for those of Mule 6, that resulted positive for the former in a
sample collected on day 12 Post-IS. Despite the spot presence of
EHV 1 in this subject, it never presented clinical signs, rise in
temperature or thrombocytopenia.
Fig. 1 reports the trends of rectal temperature, PLT and plasma-
associated vRNA loads for the evaluation of the temporal
association between these alterations relative to each study
animal, including that of the negative control.
Hyperthermia, above 39 C, considered the only clinical sign
objectively correlated to the disease (Leroux et al., 2004), wasobserved between day 8 and 6 Pre-IS, in two mules reaching 40 C
and between day 9 and 17 Post-IS, in six subjects, with a maximum
peak of 41.1 C. In the febrile animals, hyperthermia lasted from
one to ﬁve days maximum (Fig. 1). Clinical signs were generally
absent for the whole observation period with the exception of
Mule 3, that frequently presented a profound physical depression
throughout the SP.
Following is a description of the alterations observed in the two
groups.
Group N: Mule 3 had a constant presence of vRNA for the whole
SP with a peak of log10 5.10 copies/ml on day 17 Post-IS,
concomitant with a febrile episode, and repeated PLT drops below
the threshold level, especially in the initial period of the SP and in
particular between day 50 Pre- and day 28 Post-IS. In addition to
the aforementioned alterations of the sensorium, the subject
presented frequent mild anaemia and jaundice with a progressive
worsening of its general condition and for this was culled on day
28 Post-IS.
Mule 5 registered a viremic peak of log10 6.88 copies/ml on day
17 Post-IS that was the highest value observed among all mules,
accompanied by fever that was followed by thrombocytopenia
lasting for 5 consecutive days, while mild anaemia was mostly
present during the second part of the Post-IS period.
In Mules 6, 7 and 8, clinical signs were irrelevant and in the
latter two, vRNA loads for the last two animals were detectable
only occasionally, at lower levels to those observed in the other
mules, between log10 3.06 and 4.05 copies/ml, while Mule 6 was
positive just on day 19 Post-IS, with a low vRNA value of log10
1.97 copies/ml.
Group P: Mule 1 presented two viremic peaks, log10 5.69 and
6.13 copies/ml, with the higher observed during the Pre-IS. On both
occasions, the viral peaks were accompanied by fever and
thrombocytopenia. Only on day 15 Post-IS did the animal present
a moderate depression of the sensorium, in concomitance with the
second viremic peak, accompanied by a PLT drop that lasted for
seven consecutive days.
Mule 2 registered a viremic peak of log10 5.4 copies/ml, the day
following the end of IS, together with a transient low fever and
thrombocytopenia, while anaemia was present at the end of the
IS.
As for Mule 1, Mule 4 also presented a double vRNA peak, log10
5.93 and 6.02 copies/ml, with the higher value recorded however
during the Post-IS period and had a constant presence of vRNA
during the whole SP. Repeated PLT drops in this subject were
observed between day 22 Pre-IS and day 15 Post-IS. The same mule
presented alterations of the sensorium, with mild depression,
anaemia and oedema, subsequently to the second viremic peak.
Mule 9 presented detectable levels of vRNA constantly below
log10 2.96 copies/ml, between day 11 and 22 Post–IS, with just a PLT
decline on day 14 Post-IS.
For Mule 10, two febrile episodes were observed; the ﬁrst
during the Pre-SP and the other on day 16 Post-IS, the latter was
associated to thrombocytopenia, preceded by a vRNA peak with a
value of log10 3.91 copies/ml.
3.3. Total viral nucleic acid in tissues
The day on which the subjects were slaughtered, as also the
results of the total viral nucleic acid/105 CE for the different tissues
examined, are reported in Table 2. In the majority of the animals
examined, the spleen had the highest viral load, followed by the
spinal cord, liver, kidney and lymph nodes, with the exception of
Mule 3 and 10, in which the highest total nucleic acid values were
respectively found in the spinal cord and kidney. The remaining
tissues were found positive with values less than 1.6 copies/105 CE
or undetectable.
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and adrenal glands of two different subjects, Mule 3 and 5, as well as,
inthe lymphnodesofallanimals except forMule6. Inaddition, inthis
group, the positive animals had overall, higher values than those
obtained for the other group, especially for the spleen tissue of Mule
5, with 487 copies/105CE. For Group P, the maximum values were
detected in the spleen of Mule 10, with 60.83 copies/105 CE.
Results of vRNA in nasal swabs were as following: in Mules 1, 2,
4, 5, 6 and 10, detection was sporadic (one to three samples) with
vRNA loads close to the detection limit, ranging from 0.002 and
10.74 copies/ml which were recorded between day 1 and 21 Post-IS
and were not simultaneous to the plasma vRNA peaks.
3.4. Veriﬁcation of the presence of PCR inhibiting activity
Ampliﬁcation of the endogenous gene coding for Beta-actin was
successful in all the samples that were examined by the different
PCRs described above.
3.5. Bacteriological examinations
No bacterial examinations were carried out on the nasals swabs
as there were no signs referable to respiratory diseases during the
entire SP.
3.6. Gross, histological and immunohistochemical results
No relevant gross lesions were found at necropsy. The principal
microscopic lesions observed are reported in Table 2. Moderate HS
in the cytoplasm of macrophages was evident in the spleen of all
animals, except for Mule 2. With a lesser degree of severity and at a
lower rate, the same alteration was observed in the Kupffer cells
and in the lymph nodes macrophages. In the liver of two subjects,
lymphomonocyte inﬁltrates (LI) were present in the periportal
duct areas. In the kidney of all subjects examined, LI were present
with evidence of mild to moderate membranous proliferative
glomerulonephritis in four subjects.
LI was almost constantly present in the lungs examined and
occasionally associated with the accumulation of lymphocytes at
the peribronchiolar area together with a mild thickening of the
alveolar septa. Similar inﬂammatory lesions of modest entity were
also evident in the cardiac interstitium of seven mules. LI were also
present in the brain of three animals, Mule 1, 3 and 6, prevalently
organised as lymphocytic perivascular cufﬁngs in the white matter
(lymphomonocytic leucoencephalitis): in Mule 3, LI were more
diffuse with respect to the other two subjects and were also
associated with a severe multifocal lymphocytic meningitis. Other
lesions observed were the presence of scattered foci of lympho-
cytic nodules in the adrenal gland of one subject of the ﬁve
examined and a multifocal or diffuse degeneration of the
hepatocytes of Mule 2 and 8.Fig. 2. IHC positive reaction: (a) Lung (Mule 5), (b) Adrenal gland and (c) Kidney (Mule 
resembling macrophages, randomly distributed in (a) the alveolar septa, in (b) the pars in
the kidney (c) the immunoreactivity is detectable within the lymphoplasmacytic inﬁltPreliminary IHC, in some of the tissues examined belonging to
three subjects of Group P and four subjects of Group N, detected
p26 antigen in the cytoplasm of a few scattered macrophages in the
inﬂammatory lesions of the kidney, liver, lung, heart and adrenal
gland (Fig. 2).
The negative control animal did demonstrate any alterations for
the clinical, haematological and histological parameters and was
constantly virologically and serologically negative for EIAV.
4. Discussion
The current study reports the ﬁrst description relative to the
evolution of the clinical, quantitative virological and pathological
ﬁndings in ten asymptomatic, naturally infected mules, presenting
different AGIDT serological reactivity patterns that were subjected
to pharmacological immune suppression for the reactivation of the
EIA infection. On enrolment, none of the mules were presenting
clinical signs referable to EIA, nor were they in the viremic phase of
the infection as all of them were reacting negatively for the
presence of plasma vRNA. The animals were however conﬁrmed as
infected by EIAV, as proviral cDNA was detected in their buffy coat,
using a conventional PCR as described by Cappelli et al. (2011) and,
as mentioned further on, products of this PCR were used for a
preliminary sequencing of the strains involved. This condition is
ascribable to an inapparent state of infection. In further support of
this, EIA serological diagnosis had been carried out at least six
months prior to the beginning of the SP and even then, the study
animals were in the inapparent phase of the disease. This status is
similar to that described by Hammond et al. (2000) for EIA
persistently infected horses during the asymptomatic phase, in the
absence of stress related conditions (Harrold et al., 2000).
As in other studies conducted for the investigation of EIAV
replication, through the quantitation of the vRNA loads in plasma
from which the cellular part was removed, the PCR could have also
ampliﬁed proviral DNA that could have been present in the sample.
In our case we did not include treatment with DNAase, as also
omitted by other authors (Quinlivan et al., 2007), as in trails we
conducted there was a decrease in the amount of the vRNA
ampliﬁed. Even in the absence of DNAase treatment, the amount of
proviral DNA is minimal because, as stated in the introduction,
EIAV replication occurs only in differentiated tissue macrophages.
In addition, also as reported by Harrold et al. (2000), during the
different disease states, peripheral blood mononuclear cells were
found to contain less than 1% of the cellular viral burden.
During the present study, active viral replication began in ﬁve
mules belonging to both AGIDT serological groups (Fig. 1) during
the Pre-IS period and coincided to when the subjects were put
together. Such an event presumably represented a stress due to the
new management these were experiencing. All the animals were
subsequently subjected to an experimentally controlled immune
suppression, using the same protocol employed in horses (Kono10). Scattered cytoplasmic immunoreactivity in mononuclear cells morphologically
termedia of the adrenal gland and in (c) the renal interstitium. In the lung (a) and in
rates. Anti-p26 Mab, Hematoxylin counterstain, 40.
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vRNA peaking in all of them, even if in one subject, virus replication
was detected just on one day. Administration of dexamethasone in
these animals proved to be effective in inducing immune
suppression as veriﬁed by their delayed hypersensitivity reaction.
This condition caused the recrudescence of EIA simultaneously to
IS, with reactivation or increase of EIAV replication, that reached
levels higher than those observed in the Pre-IS period, accompa-
nied by fever and PLT decline in nine of ten study subjects mules.
Differently from what was observed in similar experiments
conducted in horses (Craigo et al., 2007; Tumas et al., 1994; Kono
et al., 1976), in our study, viral peaking was exclusively accompa-
nied by mild signs that only a careful daily clinical examination was
capable of detecting. With the exception of Mule 3, which was
continually depressed, neither the high temperature, that was
however transient, nor the thrombocytopenia recorded in the
other nine mules profoundly altered their general state. If a
pathogenic threshold was to be determined in the present study, as
reported for the horse, this is between log10 4.20 and 6.88 copies/
ml of plasma vRNA, which is inferior to that reported by Cook et al.
(2003). Such lower levels could be due to the use of a different PCR
method with a lower recovery rate to that reported by the same
authors (Cook et al., 2002).
Although the clinical ﬁndings observed throughout the SP
corroborated the inapparent phase of infection, they did not
correlate with the dynamics of EIAV replication, typical of its
reactivation.
On the whole, our mules presented a clinical behaviour similar
to that described in donkeys which have plasma vRNA burdens that
are 1000-fold less than that of the horse (Cook et al., 2001), but
with vRNA peaks that can be described as closer to those reported
in acute forms or reactivation of EIA in the latter species.
vRNA replication behaviour observed in the present study is
another important feature in the evolution of EIA infection in these
animals, as there were important ﬂuctuations in the plasma viral
levels, with some animals having periods of vRNA negativity,
during which testing of the plasma by molecular methods could
have falsely led in classifying them as negative.
When comparing the vRNA replication levels throughout the
study period in the two groups, even if the proportion of positive
samples were greater for Group P, the interval of the plasma vRNA
values observed was however similar; within a range of log10 2.0–
6.8 copies/ml for Group N and log10 3.0–6.1 copies/ml for Group P,
with the highest titre observed in the former. On the basis of these
observations, it would seem that viral replication is independent of
the serological reactivity, at least for p26, which is the antigen used
in the AGIDT, as EIAV replication was indifferently observed within
the animals belonging to the different groups. This result is in
partial contrast with the assumption that the EIA immune status
depends on its antigenic stimulation (Cook et al., 2003). In our case,
there were mules, Mule 3, 5 and 8, that even if experiencing a
continuous EIAV replication, showed an AGIDT antibody response
continually low and not attributable to what could be an initial
phase of the infection (Table 1).
For this reason, mules having an equivocal serological response
and with ﬂuctuating vRNA plasma loads could pass undetected
when using tests of low diagnostic sensitivity, as is the case of the
AGIDT (Issel et al., 2013) and also in some cases the PCR when virus
levels are below the detection limit and/or due to the intrinsic
genetic variability of EIAV.
Relative to the quantitation of the total viral nucleic acid loads,
we adopted a method that even if different from that described by
other authors in horses (Harrold et al., 2000) and in mules (Spyrou
et al., 2003), gave overall results generally in agreement with those
reported by these authors, with the exception of the nervous
tissue, for which discordant results for the horse exist (Harroldet al., 2000; Kim and Casey, 1992; Kono et al., 1971). Even in the
mule, as also reported by Quinlivan et al. (2007) and Harrold et al.
(2000) for the horse, the highest viral nucleic acid loads were
constantly detected in the spleen tissue of all subjects examined,
with the exception of Mule 3 and 10.
Of note is that the greatest tissue viral nucleic acid loads were
observed in two animals of Group N, Mule 3 and 5, that are in
agreement with their highest vRNA plasma levels. Of particular
interest is whether the viral amounts detected in the brain and
spinal cord tissue of Mule 3, as well as the total viral loads and
histological lesions at this level, are correlated with the severe
depression of the sensorium the subject presented throughout the
study and was for this the ﬁrst to be slaughtered.
In relation to the persistence of EIAV in tissues, moderate to
high levels of viral nucleic acids were still detectable even in Mule
2 and 4, slaughtered between 30 and 60 days from when they had
experienced their highest vRNA peaks. A further conﬁrmation of
this is that animals in which viral nucleic acid was absent
corresponded to those with relatively lower levels and proportion
of positive samples for plasma vRNA, even if this could be due to a
low sensitivity and/or speciﬁcity of the PCR method employed for
the strains involved that should be further analysed. In fact for
Mule 6, the animal with the lowest virological/serological
reactivity, these results could be attributed to a particular strain
of EIAV or to the capability of the animal of efﬁciently controlling
the infection. This hypothesis may be supported by the presence of
the p26 antigen observed with IHC in the lung, adrenal gland and
liver of the same animal.
A preliminary study that we conducted on the sequencing of the
gag gene of the EIAV strains of the study animals, using the method
reported by Cappelli et al. (2011), Mule 6 had a sequence identity of
81% with EIAV Rom-4 (GU060662.1) while the other strains had a
sequence identity that varied from 77 to 96% to previously
identiﬁed European EIAV strains. Further phylogeny studies are
being carried out on the EIAV strains involved in this study and will
be discussed in another article.
Persistence of EIAV for long intervals at tissues levels, as well as
in the plasma, implies that notwithstanding the inapparent state of
infection and a limited AGIDT reactivity, animals may act as
efﬁcient reservoirs in which viral replication reaching high levels
can be retriggered under particular conditions such as those
described in this paper.
The microscopic lesions observed in the various tissues are
similar to those reported in the chronic forms of EIA in ponies (Oaks
et al., 2004) and mules (Spyrou et al., 2003) as also the IHC positivity
to what was described by Bolfa et al. (2013) for the horse, using
immunoﬂuorescence. In relation to this, lesions and IHC reactivity
described in the lung require further investigations to verify the
possible viral release through the respiratory tract, a transmission
route not previously considered for EIA. Even if our ﬁndings do not
support this assumption, as low viral loads were detected in the
nasals swabs of our animals, this is in contrast to what was described
by Quinlivan et al. (2007) who reported higher amounts of RNA
copies/ml in nasal swab material in symptomatic horses. Detection
of different levels of vRNA in this sample type could be due to the
species involved or time since infection, which in the case of the Irish
outbreak, was very recent, or also, as previously mentioned, due to
the sensitivity of the PCR method, employed.
Further to what was reported by Spyrou et al., 2003; this paper
describes the presence of inﬂammatory lesions in the myocardium
and brain of some of the animals examined. Pathological alterations
in the brain tissue deﬁned as granulomatous ependymitis (McIl-
wraith and Kitchen, 1978) or as periventricular lymphohistiocytic
leukoencephalitis (Oaks et al., 2004) were occasionally described for
horses and ponies but not considered as relevant in an EIA infection.
Preliminary trials using IHC conﬁrmed that the histological lesions
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nervous tissue that lack conﬁrmation due to the presence of an
aspeciﬁc background. Relative to the absence or low amounts of viral
nucleic acid in tissues that presented histological lesions and/or IHC
positivity, this could be attributed to the degradation that the former
could undergo during sample storage or to the sensitivity of the PCR
method, in terms of detection limit and the possible genetic
variabilityof the PCR target. Ontheotherhand, the IHC methodhas as
target, an antigen that is less degradable than genetic material and is
also highly conserved in EIAV, as only one serotype is currently
known for this virus.
In this study, it was not possible to correlate parameters such as
age and breed with the evolution of the EIA infection as the set of
animals within the groups were heterogeneous. Relative to the sexof
the animals, in the mule population, it is the females that are kept as
working animals as they are more docile and therefore our study
group is representative of the ﬁeld population structure. In addition,
the identiﬁcation number was arbitrarily assigned according to the
succession of the recruitment time; therefore the fact that Mules 1–
5 had a more intensive evolution of EIA is casual. As mentioned
earlier, even the viral strains infecting these subjects were to some
extent genetically different. The evolution of EIA in our study is on
individual basis and is a result of the multiple host and viral factors
that are in this context difﬁcult to identify but which however does
not correlate with the type of AGIDT reactivity.
According to the current European Union Directive (2009/156)
on the movement of equidae between member states it is sufﬁcient
to declare freedom of disease just on the absence of clinical signs.
In the light of the inapparent phase of EIA infection described in
horses and mules, such an afﬁrmation does not fully guarantee the
true health status of the animal, which also might not be accurately
deﬁned with the sole use of AGIDT. For this, the perception that
would rise from the use of a passive surveillance is that in the
absence of clinical signs, or a negative AGIDT reaction, an EIA
infected equid represents a low transmission risk.
The increasing knowledge on the evolution of EIA, even in
mules, as also the data generated from the surveillance conducted
in Italy over a period of six years (Scicluna et al., 2013) provided the
basis for the set up of an active risk based serological surveillance,
using the ELISA as a screening test.
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